Harrow (NASDAQ:HROW) Stock Price Down 4.6% – Time to Sell?

Harrow, Inc. (NASDAQ:HROW)’s share price dropped 4.6% on Wednesday . The stock traded as low as $25.17 and last traded at $25.74. Approximately 93,816 shares changed hands during trading, a decline of 81% from the average daily volume of 501,370 shares. The stock had previously closed at $26.98.

Wall Street Analyst Weigh In

HROW has been the subject of several research analyst reports. B. Riley decreased their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research note on Wednesday, December 4th. HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Harrow in a research note on Tuesday.

Harrow Stock Down 2.1 %

The firm has a market capitalization of $940.56 million, a PE ratio of -28.01 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The company’s fifty day simple moving average is $30.01 and its 200-day simple moving average is $38.63.

Institutional Investors Weigh In On Harrow

A number of large investors have recently made changes to their positions in the stock. Woodmont Investment Counsel LLC grew its holdings in shares of Harrow by 0.5% during the fourth quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company’s stock valued at $2,731,000 after buying an additional 445 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Harrow by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company’s stock valued at $582,000 after purchasing an additional 585 shares during the period. Swiss National Bank lifted its position in Harrow by 1.0% during the fourth quarter. Swiss National Bank now owns 59,300 shares of the company’s stock valued at $1,990,000 after purchasing an additional 600 shares during the period. Quest Partners LLC acquired a new position in Harrow during the third quarter valued at $29,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Harrow by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after purchasing an additional 727 shares during the period. 72.76% of the stock is owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.